Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24254532 | 0.81 | MEN1 (0.66) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL4773746 | 0.80 | KDM4E (0.56) | ALDH1A1HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL7406083 | 0.74 | MEN1 (0.70) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL7250492 | 0.74 | MMP13 (0.75) | — | |
| SCHEMBL7251379 | 0.73 | ADAMTS7 (0.75) | ALDH1A1PKMSMN1; SMN2LMNATP53 | |
| SCHEMBL22491610 | 0.73 | MEN1 (0.69) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL16000506 | 0.73 | MEN1 (0.64) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL5803633 | 0.72 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL5791545 | 0.71 | SMN1; SMN2 (0.60) | ALDH1A1PKMSMN1; SMN2POLBKMT2A | |
| SCHEMBL388198 | 0.71 | MMP13 (0.61) | ALDH1A1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2022035804-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP1 | ALDH1A1 1387/4885PKM 3685/4885HSD17B10 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.